Related Experiment Video
Updated: Apr 16, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Statin use after acute myocardial infarction by patient complexity: are the rates right?
John M Brooks1, Elizabeth Cook, Cole G Chapman
1*Arnold School of Public Health, University of South Carolina, Columbia, SC †Clinical Trials Statistical & Data Management Center, University of Iowa, Iowa City, IA ‡Arnold School of Public Health, University of South Carolina, Columbia, SC §Department of Pharmacy Practice and Science, University of Iowa ∥University of Iowa College of Public Health, Iowa City ¶Schneider Research Associates, LLC, Des Moines, IA #Health Economics Research Group, Brunel University London, Uxbridge, UK **University of Iowa College of Public Health, Iowa City, IA.
Insights
Higher statin use after acute myocardial infarction (AMI) improves survival in noncomplex patients but presents tradeoffs between survival and adverse events in complex patients. Statin prescribing for complex AMI patients needs careful consideration.
Area of Science:
- Cardiovascular Medicine
- Health Services Research
- Pharmacotherapy
Background:
- Statin therapy is recommended post-acute myocardial infarction (AMI), but actual use is suboptimal, varies geographically, and decreases with patient complexity.
- Existing clinical trials often exclude complex patients, limiting evidence for optimal statin prescribing in this population.
Purpose of the Study:
- To evaluate the benefits and risks of increased statin utilization after AMI, stratified by patient complexity.
- To inform evidence-based guidelines for statin prescribing in diverse AMI patient groups.
Main Methods:
- Analysis of Medicare fee-for-service patients experiencing AMI between 2008-2009.
- Utilized instrumental variable methods, employing regional prescribing variations as instruments to assess statin intensity's impact on survival, adverse events, and cost.
- Stratified analyses by patient complexity.
Main Results:
- Increased statin rates in noncomplex AMI patients correlated with improved survival and minimal additional adverse event risk.
- In complex AMI patients, higher statin rates demonstrated a balance between enhanced survival and increased adverse event rates.
- Provider prescribing patterns suggested individualized statin management based on perceived patient risks.
Conclusions:
- Findings for noncomplex AMI patients align with existing evidence on statin benefits.
- For complex AMI patients, higher statin use revealed previously undocumented survival gains alongside elevated adverse event risks.
- Policy initiatives advocating for universal statin use in complex AMI populations require reevaluation, considering the observed risk-benefit tradeoffs.
Background:
Guidelines suggest statin use after acute myocardial infarction (AMI) should be close to universal in patients without safety concerns yet rates are much lower than recommended, decline with patient complexity, and display substantial geographic variation. Trial exclusions have resulted in little evidence to guide statin prescribing for complex patients.
Objective:
To assess the benefits and risks associated with higher rates of statin use after AMI by baseline patient complexity.
Research Design:
Sample includes Medicare fee-for-service patients with AMIs in 2008-2009. Instrumental variable estimators using variation in local area prescribing patterns by statin intensity as instruments were used to assess the association of higher statin prescribing rates by statin intensity on 1-year survival, adverse events, and cost by patient complexity.
Results:
Providers seem to have individualized statin use across patients based on potential risks. Higher statin rates for noncomplex AMI patients were associated with increased survival rates with little added adverse event risk. Higher statin rates for complex AMI patients were associated with tradeoffs between higher survival rates and higher rates of adverse events.
Conclusions:
Higher rates of statin use for noncomplex AMI patients are associated with outcome rate changes similar to existing evidence. For the complex patients in our study, who were least represented in existing trials, higher statin-use rates were associated with survival gains and higher adverse event risks not previously documented. Policy interventions promoting higher statin-use rates for complex patients may need to be reevaluated taking careful consideration of these tradeoffs.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management
01:14Myocarditis III: Medical Management
01:27Coronary Artery Disease V: Interprofessional Care